2025年11月25日批准, 阿布扎比成为第一个为脊髓肌肉萎缩提供诺华的一次性基因疗法的地区。 Abu Dhabi became the first region to offer Novartis’ one-time gene therapy for spinal muscular atrophy, approved November 25, 2025.

阿布扎比已成为全球第一个管理ITVISMA的区域,ITVISMA是诺华公司研制的脊椎肌肉萎缩(SMA)一次性基因疗法。 Abu Dhabi has become the first region globally to administer ITVISMA, a one-time gene therapy for spinal muscular atrophy (SMA), developed by Novartis. 经阿联酋卫生部于2025年11月25日批准, 治疗对象为二岁及二岁以上的经确认为SMN1基因突变的病人, 目的是通过替换缺失的基因来恢复运动功能。 Approved by the UAE’s Department of Health on November 25, 2025, the treatment targets patients aged two and older with a confirmed SMN1 gene mutation, aiming to restore motor function by replacing the missing gene. 这一里程碑突出了阿布扎比在精密医学和医疗旅游方面的领导作用,将阿联酋列为美国之后最早提供治疗的国家之一。 Administered at Sheikh Khalifa Medical City, the milestone highlights Abu Dhabi’s leadership in precision medicine and medical tourism, placing the UAE among the first countries—after the U.S.—to offer the therapy. 来自卫生部、诺华州和保健合作伙伴的官员称其为促进罕见疾病的护理迈出了重大一步。 Officials from the DoH, Novartis, and healthcare partners called it a major step in advancing care for rare diseases.